Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: A nonparametric population pharmacokinetic study

Therapeutic Drug Monitoring

Volumn 29, Issue 2, 2007, Pages 177-184

  Bertholle Bonnet, V ^a   Bleyzac, N ^a,b   Galambrun, C ^a   Mialou, V ^a   Bertrand, Y ^a   Souillet, G ^a   Aulagner, G ^a,b  

^a HÔPITAL DEBROUSSE   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Busulfan; Pediatric; Pharmacokinetics

Indexed keywords

BUSULFAN;

ARTICLE; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HEMOGLOBINOPATHY; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL;

ADOLESCENT; ALKYLATING AGENTS; AREA UNDER CURVE; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; METABOLIC CLEARANCE RATE; PROSPECTIVE STUDIES;

EID: 34248196538     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318039b478     Document Type: Article

References (28)

1. Dix SP,Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230.
2. Hassan M, Ehrsson H, Ljungman P. Aspect concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma. 1996;22:395-407.
3. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patient undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61.
4. Chattergoon DS, Saunders EF, Klein J, et al. An improved limited sampling method for individualized busulfan dosing in bone marrow transplantation in children. Bone Marrow Transplant. 1997;20:347-354.
5. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998;20:543-549.
6. Vassal G, Challine D, Koscielny S, et al. Chronopharmacology of highdose busulfan in children. Cancer Res. 1993;53:1534-1537.
7. Jelliffe RW, Schumitzky A, Van Guilder M. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptative control. Ther Drug Monit. 1993;15:380-393.
8. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of pediatric bone marrow recipient using a test-dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28:743-751.
9. Mc Cune J, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet. 2000;39:155-165.
10. Vassal G, Fischer A, Challine D, et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood. 1993;82:1030-1034.
11. Vassal G. Pharmacologically-guided dose adjustment of busulfan in highdose chemotherapy regimens: rationale and pitfalls. Anticancer Res. 1994;14:2363-2370.
12. Poonkuzhali B, Chandy M, Srivastava A. GSTactivity influences busulfan pharmacokinetics in patients with β thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos. 2001;29:264-267.
13. Hassan M, Fasth A, Gerritsen B, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant. 1996;18:843-850.
14. Tod M, Mentre F, Merle Y, et al. Robust design for the estimation of hyperparameters in population pharmacokinetics. J Pharmacokinet Biopharm. 1998;26:689-711.
15. Schiltmeyer B, Klingebiel T, Schwab M, et al. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol. 2003;52:209-216.
16. Laboratory of Applied Pharmacokinetics. USC* Pack P.C. Collection Clinical Research Programs, version 10.7. Los Angeles: University of Southern California, School of Medicine; 1995.
17. Bleyzac N, Barou P, Aulagner G. Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma. J Chromatogr B Biomed Sci Appl. 2000;742:427-432.
18. Leary R, Jelliffe R, Schumitzky A, et al. A unified parametric/ nonparametric approach to population PK/PD modelling. Annual Meeting of the Population Approach Group in Europe. Paris, June 6-7, 2002.
19. Bustad A, Terziivanov D, Leary R, et al. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet. 2006;45:365-383.
20. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal oriented, individualized drug therapy. Clin Pharmacokinet. 1998;34:57-77.
21. Jelliffe RW, Gomis P, Tahani B, et al. A population pharmacokinetic model of Trimethoprim in patients with pneumocystis pneumonia, made with parametric and non parametric method. Ther Drug Monit. 1997;19:450-459.
22. Jelliffe RW, Tahani B. Effect of assumptions concerning assay error patterns upon pharmacokinetic parameter values and model behavior. J Vet Pharmacol Ther. 1994;17:105-109.
23. Vassal G, Gouyette A, Hartmann O, et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol. 1989;24:386-390.
24. Tran HT, Madden T, Petropoulos D, et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant. 2000;26:463-470.
25. Sheiner L, Beal S. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
26. Wiela-Hojenska A, Gorczynska E, Orzechowska-Juzwenko K, et al. Metabolic functions of the liver during chemotherapy in children with acute lymphoblastic leukemia. Int J Clin Pharm Ther. 2001;39:246-250.
27. Pawlowska AB, Blazar BR, Angelucci E, et al. Relationship of plasma pharmacokinetics of high dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant. 1997;20:915-920.
28. Bullock J, Smith P, Booker B, et al. Development of a pharmacokinetic and Bayesian optimal sampling model for individualisation of oral busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 2006;28:62-66.